# Meike Vogler

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 37 papers | 1,527 citations | 18 h-index | 39 g-index |
| 39 ext. papers | 1,758 ext. citations | 6.9 avg, IF | 4.71 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 37 | Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. *Blood*, **2009**, 113, 4403-13 | 2.2 | 263 |
| 36 | BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. *Blood*, **2011**, 117, 7145-54 | 2.2 | 140 |
| 35 | Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. *Cancer Research*, **2008**, 68, 7956-65 | 10.1 | 137 |
| 34 | Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. *Cancer Research*, **2009**, 69, 2425-34 | 10.1 | 133 |
| 33 | Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. *Blood*, **2009**, 113, 1710-22 | 2.2 | 122 |
| 32 | ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. *British Journal of Haematology*, **2013**, 163, 139-42 | 4.5 | 82 |
| 31 | Targeting BCL2-Proteins for the Treatment of Solid Tumours. *Advances in Medicine*, **2014**, 2014, 943648 | 2.3 | 62 |
| 30 | Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. *Cancer Research*, **2005**, 65, 10502-13 | 10.1 | 62 |
| 29 | Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. *Haematologica*, **2010**, 95, 1510-8 | 6.6 | 61 |
| 28 | S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. *Oncotarget*, **2018**, 9, 20075-20088 | 3.3 | 56 |
| 27 | Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment. *British Journal of Haematology*, **2017**, 178, 364-379 | 4.5 | 53 |
| 26 | Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. *Clinical Cancer Research*, **2010**, 16, 4217-25 | 12.9 | 42 |
| 25 | Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity. *Oncogene*, **2005**, 24, 7190-202 | 9.2 | 38 |
| 24 | MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. *Journal of Hematology and Oncology*, **2020**, 13, 173 | 22.4 | 26 |
| 23 | Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells. *Cancer Letters*, **2018**, 428, 160-172 | 9.9 | 24 |
| 22 | BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis. *Oncogene*, **2018**, 37, 5325-5339 | 9.2 | 22 |
| 21 | Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-X and MCL-1 leads to rapid induction of intrinsic apoptosis. *Cancer Letters*, **2020**, 482, 19-32 | 9.9 | 20 |

| | | | |
|---|---|---|---|
| 20 | BCL-x-selective BH3 mimetic sensitizes rhabdomyosarcoma cells to chemotherapeutics by activation of the mitochondrial pathway of apoptosis. *Cancer Letters*, **2018**, 412, 131-142 | 9.9 | 19 |
| 19 | Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines. *Cancers*, **2018**, 10, | 6.6 | 16 |
| 18 | The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. *Biochemical and Biophysical Research Communications*, **2011**, 408, 344-9 | 3.4 | 15 |
| 17 | Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML. *Cell Death and Disease*, **2019**, 10, 917 | 9.8 | 15 |
| 16 | Response: BH3 mimetics modulate calcium homeostasis in platelets. *Blood*, **2012**, 119, 1321-1322 | 2.2 | 12 |
| 15 | It's time to die: BH3 mimetics in solid tumors. *Biochimica Et Biophysica Acta - Molecular Cell Research* , **2021**, 1868, 118987 | 4.9 | 11 |
| 14 | -Mutated Rhabdomyosarcoma Cells Are Vulnerable to Mitochondrial Apoptosis Induced by Coinhibition of MEK and PI3K. *Cancer Research*, **2018**, 78, 2000-2013 | 10.1 | 10 |
| 13 | BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models. *Cell Death and Disease*, **2020**, 11, 769 | 9.8 | 10 |
| 12 | A direct comparison of selective BH3-mimetics reveals BCL-X, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma. *British Journal of Cancer*, **2020**, 122, 1544-1551 | 8.7 | 9 |
| 11 | Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma. *Haematologica*, **2020**, 105, 2150-2163 | 6.6 | 9 |
| 10 | Response: Microenvironment-dependent resistance to ABT-737 in chronic lymphocytic leukemia. *Blood*, **2009**, 114, 2561-2562 | 2.2 | 9 |
| 9 | Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies. *Haematologica*, **2019**, 104, 1016-1025 | 6.6 | 8 |
| 8 | Identification of Smac mimetics as novel substrates for p-glycoprotein. *Cancer Letters*, **2019**, 440-441, 126-134 | 9.9 | 7 |
| 7 | Selective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations. *Biological Chemistry*, **2019**, 400, 181-185 | 4.5 | 6 |
| 6 | Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways. *Cell Death and Differentiation*, **2020**, 27, 1878-1895 | 12.7 | 5 |
| 5 | Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large B-cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis. *International Journal of Cancer*, **2020**, 147, 1485-1498 | 7.5 | 4 |
| 4 | DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition. *Biomolecules*, **2020**, 10, | 5.9 | 3 |
| 3 | Small Molecule XIAP Inhibitors Cooperate with TRAIL to Trigger Apoptosis in Childhood Acute Leukemia Cells and Overcome Bcl-2-Mediated Resistance. *Blood*, **2008**, 112, 857-857 | 2.2 | 2 |

| | | | |
|---|---|---|---|
| 2 | Pediatric multicellular tumor spheroid models illustrate a therapeutic potential by combining BH3 mimetics with Natural Killer (NK) cell-based immunotherapy.. *Cell Death Discovery*, **2022**, 8, 11 | 6.9 | 2 |
| 1 | Unleashing the power of NK cells in anticancer immunotherapy. *Journal of Molecular Medicine*, **2021**, 1 | 5.5 | 2 |